Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab-A Randomized Controlled Trial

American Journal of Ophthalmology

Volumn 149, Issue 3, 2010, Pages

  Gharbiya, Magda ^a   Giustolisi, Rosalia ^a   Allievi, Francesca ^a   Fantozzi, Nicoletta ^a   Mazzeo, Luigi ^a   Scavella, Vittorio ^a   Gabrieli, Corrado Balacco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INFECTIOUS ENDOPHTHALMITIS; MALE; MYOPIC CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA FOVEA; SUBRETINAL NEOVASCULARIZATION; THICKNESS; TREATMENT DURATION; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 76749092670     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.10.010     Document Type: Article

References (30)

1. Yoshida T., Ohno-Matsui K., Yasuzumi K., et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110 (2003) 1297-1305
2. Ohno-Matsui K., Yoshida T., Futagami S., et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br J Ophthalmol 87 (2003) 570-573
3. Chan W.M., Ohji M., Lai T.Y.Y., Liu D.T.L., Tano Y., and Lam D.S.C. Choroidal neovascularization in pathological myopia: an update in management. Br J Ophthalmol 89 (2005) 1522-1528
4. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-Year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 108 (2001) 841-852
5. Chan W.M., Lai T.Y.Y., Wong A.L., Liu D.T.L., and Lam D.S.C. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91 (2007) 174-179
6. Blinder K.J., Blumenkranz M.S., Bressler N.M., et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 110 (2003) 667-673
7. Nguyen Q.D., Shah S., Tatlipinar S., et al. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 89 (2005) 1368-1370
8. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
9. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
10. Emerson M.V., Lauer A.K., Flaxel C.J., et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27 (2007) 439-444
11. Goff M.J., Johnson R.N., McDonald H.R., et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 27 (2007) 432-438
12. Lazic R., and Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245 (2007) 68-73
13. Costa R.A., Jorge R., Calucci D., et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 47 (2006) 4569-4578
14. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
15. Feiner L., Barr E.E., Shui Y.B., Holekamp N.M., et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 26 (2006) 882-888
16. Fung A.E., Rosenfeld P.J., and Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (2006) 1344-1349
17. Bashshu Z.F., Schaka A.I., Hama R., et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular de generation. Arch Ophthalmol 125 (2007) 1357-1361
18. Sadda S.R., Wu Z., Walsh A.C., et al. Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 113 (2006) 285-293
19. Tong J.P., Chan W.M., Liu D.T., et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141 (2006) 456-462
20. Chan W.M., Lai T.Y.Y., Chan K.P., et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 28 (2008) 1308-1313
21. Mordenti J., Cuthbertson R.A., Ferrara N., et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27 (1999) 536-544
22. Klettner A., and Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 49 (2008) 4523-4527
23. Carneiro A., Falcao M., Pirraco A., et al. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res 88 (2009) 522-527
24. Chan W.M., Lai T.Y., Liu D.T., and Lam D.S. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 93 (2009) 150-154
25. Gharbiya M., Allievi F., Mazzeo L., and Gabrieli C.B. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 147 (2009) 84-93
26. Lai T.Y., Chan W.M., Liu D.T., and Lam D.S. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 29 (2009) 750-756
27. Raftery J., Clegg A., Jones J., et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 91 (2007) 1244-1246
28. Shahar J., Avery R.L., Heilweil G., et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26 (2006) 262-269
29. Heiduschka P., Fietz H., Hofmeister S., et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48 (2007) 2814-2823
30. Keane P.A., Liakopoulos S., Chang K.T., et al. Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol 92 (2008) 1081-1085